The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells

Journal of Immunology

Volumn 189, Issue 6, 2012, Pages 2727-2734

  Ainsua Enrich, Erola ^a,b   Álvarez Errico, Damiana ^a,b   Gilfillan, Alasdair M ^c   Picado, César ^b,d   Sayós, Joan ^e,f   Rivera, Juan ^g   Martín, Margarita ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^g NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FC EPSILON RECEPTOR I; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; PHOSPHOLIPASE C GAMMA; PLECKSTRIN; PROTEIN KINASE LYN; PROTEIN KINASE SYK; SHORT HAIRPIN RNA; SRC HOMOLOGY 3 BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; BIOTINYLATION; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL ACTIVATION; CELL FUNCTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MAST CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL DEGRANULATION; CELL LINE; HUMANS; MAST CELLS; RECEPTORS, IGE; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84866153308     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200380     Document Type: Article

References (44)

1. Galli, S. J., J. Kalesnikoff, M. A. Grimbaldeston, A. M. Piliponsky, C. M. Williams, and M. Tsai. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23: 749-786. (Pubitemid 40563184)
2. Galli, S. J., M. Grimbaldeston, and M. Tsai. 2008. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8: 478-486. (Pubitemid 351733419)
3. Mekori, Y. A., C. K. Oh, and D. D. Metcalfe. 1995. The role of c-Kit and its ligand, stem cell factor, in mast cell apoptosis. Int. Arch. Allergy Immunol. 107: 136-138.
4. Rönnstrand, L. 2004. Signal transduction via the stem cell factor receptor/c-Kit. Cell. Mol. Life Sci. 61: 2535-2548. (Pubitemid 39586516)
5. Alvarez-Errico, D., E. Lessmann, and J. Rivera. 2009. Adapters in the organization of mast cell signaling. Immunol. Rev. 232: 195-217.
6. Ren, R., B. J. Mayer, P. Cicchetti, and D. Baltimore. 1993. Identification of a tenamino acid proline-rich SH3 binding site. Science 259: 1157-1161. (Pubitemid 23085353)
7. Deckert, M., S. Tartare-Deckert, J. Hernandez, R. Rottapel, and A. Altman. 1998. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 9: 595-605. (Pubitemid 28557588)
8. Maeno, K., K. Sada, S. Kyo, S. M. Miah, K. Kawauchi-Kamata, X. Qu, Y. Shi, and H. Yamamura. 2003. Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase. J. Biol. Chem. 278: 24912-24920. (Pubitemid 37548651)
9. Ueki, Y., C. Y. Lin, M. Senoo, T. Ebihara, N. Agata, M. Onji, Y. Saheki, T. Kawai, P. M. Mukherjee, E. Reichenberger, and B. R. Olsen. 2007. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 128: 71-83. (Pubitemid 46048888)
10. Hatani, T., and K. Sada. 2008. Adaptor protein 3BP2 and cherubism. Curr. Med. Chem. 15: 549-554. (Pubitemid 351516811)
11. Guettler, S., J. LaRose, E. Petsalaki, G. Gish, A. Scotter, T. Pawson, R. Rottapel, and F. Sicheri. 2011. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 147: 1340-1354.
12. Levaot, N., O. Voytyuk, I. Dimitriou, F. Sircoulomb, A. Chandrakumar, M. Deckert, P. M. Krzyzanowski, A. Scotter, S. Gu, S. Janmohamed, et al. 2011. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 147: 1324-1339.
13. Deckert, M., and R. Rottapel. 2006. The adapter 3BP2: how it plugs into leukocyte signaling. Adv. Exp. Med. Biol. 584: 107-114.
14. Yu, Z., M. Maoui, Z. J. Zhao, Y. Li, and S. H. Shen. 2006. SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J. 273: 2195-2205.
15. Foucault, I., S. Le Bras, C. Charvet, C. Moon, A. Altman, and M. Deckert. 2005. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 105: 1106-1113. (Pubitemid 40170882)
16. de la Fuente, M. A., L. Kumar, B. Lu, and R. S. Geha. 2006. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol. Cell. Biol. 26: 5214-5225. (Pubitemid 44036193)
17. Chen, G., I. D. Dimitriou, J. La Rose, S. Ilangumaran, W. C. Yeh, G. Doody, M. Turner, J. Gommerman, and R. Rottapel. 2007. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol. Cell. Biol. 27: 3109-3122. (Pubitemid 46581322)
18. Shukla, U., T. Hatani, K. Nakashima, K. Ogi, and K. Sada. 2009. Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT. J. Biol. Chem. 284: 33719-33728.
19. Jevremovic, D., D. D. Billadeau, R. A. Schoon, C. J. Dick, and P. J. Leibson. 2001. Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. J. Immunol. 166: 7219-7228. (Pubitemid 32525595)
20. Saborit-Villarroya, I., J. M. Del Valle, X. Romero, E. Esplugues, P. Lauzurica, P. Engel, and M. Martín. 2005. The adaptor protein 3BP2 binds human CD244 and links this receptor to Vav signaling, ERK activation, and NK cell killing. J. Immunol. 175: 4226-4235. (Pubitemid 41361956)
21. Saborit-Villarroya, I., A. Martinez-Barriocanal, I. Oliver-Vila, P. Engel, J. Sayos, and M. Martin. 2008. The adaptor 3BP2 activates CD244-mediated cytotoxicity in PKC- and SAP-dependent mechanisms. Mol. Immunol. 45: 3446-3453.
22. Sada, K., S. M. Miah, K. Maeno, S. Kyo, X. Qu, and H. Yamamura. 2002. Regulation of FcεRI-mediated degranulation by an adaptor protein 3BP2 in rat basophilic leukemia RBL-2H3 cells. Blood 100: 2138-2144. (Pubitemid 35001249)
23. Radinger, M., B. M. Jensen, H. S. Kuehn, A. Kirshenbaum, and A. M. Gilfillan. 2010. Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood. Curr. Protoc. Immunol. Chapter 7:Unit 7 37.
24. Furumoto, Y., S. Brooks, A. Olivera, Y. Takagi, M. Miyagishi, K. Taira, R. Casellas, M. A. Beaven, A. M. Gilfillan, and J. Rivera. 2006. Cutting edge: lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J. Immunol. 176: 5167-5171.
25. Álvarez-Errico, D., I. Oliver-Vila, E. Ainsua-Enrich, A. M. Gilfillan, C. Picado, J. Sayós, and M. Martín. 2011. CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells. J. Immunol. 187: 5577-5586.
26. Tkaczyk, C., D. D. Metcalfe, and A. M. Gilfillan. 2002. Determination of protein phosphorylation in FcεRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. J. Immunol. Methods 268: 239-243. (Pubitemid 35246169)
27. Pribluda, V. S., C. Pribluda, and H. Metzger. 1994. Transphosphorylation as the mechanism by which the high-affinity receptor for IgE is phosphorylated upon aggregation. Proc. Natl. Acad. Sci. USA 91: 11246-11250. (Pubitemid 24349663)
28. Jouvin, M. H., M. Adamczewski, R. Numerof, O. Letourneur, A. Vallé, and J. P. Kinet. 1994. Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J. Biol. Chem. 269: 5918-5925. (Pubitemid 24242971)
29. Parravicini, V., M. Gadina, M. Kovarova, S. Odom, C. Gonzalez-Espinosa, Y. Furumoto, S. Saitoh, L. E. Samelson, J. J. O'Shea, and J. Rivera. 2002. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat. Immunol. 3: 741-748.
30. Siraganian, R. P., R. O. de Castro, E. A. Barbu, and J. Zhang. 2010. Mast cell signaling: the role of protein tyrosine kinase Syk, its activation and screening methods for new pathway participants. FEBS Lett. 584: 4933-4940.
31. Gilfillan, A. M., and C. Tkaczyk. 2006. Integrated signalling pathways for mast-cell activation. Nat. Rev. Immunol. 6: 218-230. (Pubitemid 43290991)
32. Vig, M., and J. P. Kinet. 2009. Calcium signaling in immune cells. Nat. Immunol. 10: 21-27.
33. Ma, H. T., and M. A. Beaven. 2009. Regulation of Ca2+ signaling with particular focus on mast cells. Crit. Rev. Immunol. 29: 155-186.
34. Rivera, J., and A. M. Gilfillan. 2006. Molecular regulation of mast cell activation. J. Allergy Clin. Immunol. 117: 1214-1225, quiz 1226.
35. Siraganian, R. P. 2003. Mast cell signal transduction from the high-affinity IgE receptor. Curr. Opin. Immunol. 15: 639-646. (Pubitemid 37434071)
36. Costello, P. S., M. Turner, A. E. Walters, C. N. Cunningham, P. H. Bauer, J. Downward, and V. L. Tybulewicz. 1996. Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene 13: 2595-2605. (Pubitemid 27046115)
37. Riccaboni, M., I. Bianchi, and P. Petrillo. 2010. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov. Today 15: 517-530.
38. Villoutreix, B. O., G. Laconde, D. Lagorce, P. Martineau, M. A. Miteva, and P. Dariavach. 2011. Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening. PLoS One 6: e21117.
39. Saitoh, S., R. Arudchandran, T. S. Manetz, W. Zhang, C. L. Sommers, P. E. Love, J. Rivera, and L. E. Samelson. 2000. LAT is essential for FcεRI-mediated mast cell activation. Immunity 12: 525-535.
40. Saitoh, S., S. Odom, G. Gomez, C. L. Sommers, H. A. Young, J. Rivera, and L. E. Samelson. 2003. The four distal tyrosines are required for LAT-dependent signaling in FcεRI-mediated mast cell activation. J. Exp. Med. 198: 831-843. (Pubitemid 37087781)
41. Johnson, B. V., A. G. Bert, G. R. Ryan, A. Condina, and P. N. Cockerill. 2004. Granulocyte-macrophage colony-stimulating factor enhancer activation requires cooperation between NFAT and AP-1 elements and is associated with extensive nucleosome reorganization. Mol. Cell. Biol. 24: 7914-7930. (Pubitemid 39167442)
42. Ueki, Y., V. Tiziani, C. Santanna, N. Fukai, C. Maulik, J. Garfinkle, C. Ninomiya, C. doAmaral, H. Peters, M. Habal, et al. 2001. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat. Genet. 28: 125-126. (Pubitemid 32538054)
43. Ferguson, P. J., and H. I. El-Shanti. 2007. Autoinflammatory bone disorders. Curr. Opin. Rheumatol. 19: 492-498. (Pubitemid 47344244)
44. Miah, S. M., T. Hatani, X. Qu, H. Yamamura, and K. Sada. 2004. Point mutations of 3BP2 identified in human-inherited disease cherubism result in the loss of function. Genes Cells 9: 993-1004. (Pubitemid 39467973)